Metraipolis › archive › dc_de368dc62793
High frequency of potential phosphodiesterase type 5 inhibitor drug interactions in males with HIV infection and erectile dysfunction — Europe PMC PMID:33956843
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/33956843
- DOI
- 10.1371/journal.pone.0250607
- License (as archived)
- CC0-1.0
- Archived
- 2026-11-04T13:25:44.869Z
- SHA-256 of the archived text
d8b386553f77ae6949ffc55067e61825cf587380569ecdb990e43d47473bd466- Stable URL of this page
https://metraipolis.com/documento/dc_de368dc62793
How to cite
High frequency of potential phosphodiesterase type 5 inhibitor drug interactions in males with HIV infection and erectile dysfunction — Europe PMC PMID:33956843 — Europe PMC (en), https://europepmc.org/article/MED/33956843 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_de368dc62793 (Metraipolis archive dc_de368dc62793, sha256 d8b386553f77ae6949ffc55067e61825cf587380569ecdb990e43d47473bd466)
BibTeX
@misc{dcde368dc62793,
title = {High frequency of potential phosphodiesterase type 5 inhibitor drug interactions in males with HIV infection and erectile dysfunction — Europe PMC PMID:33956843},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/33956843},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_de368dc62793; sha256 d8b386553f77ae6949ffc55067e61825cf587380569ecdb990e43d47473bd466},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/33956843. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Objectives: We sought to determine the prevalence of phosphodiesterase type 5 inhibitor (PDE-5) mediated drug-drug interactions (DDIs) in males with HIV infection receiving antiretroviral therapy (ART) and identify factors associated with PDE-5-mediated DDIs. Methods: Male US Military HIV Natural History Study participants diagnosed with erectile dysfunction (ED) and having a PDE-5 inhibitor and potentially-interacting ART co-dispensed within 30 days were included. DDIs were defined according to criteria found in published guidelines and drug information resources. The primary outcome of interest was overall PDE-5 inhibitor-mediated DDI prevalence and episode duration. A secondary logistic regression analysis was performed on those with and without DDIs to identify factors associated with initial DDI episode. Results: A total of 235 male participants with ED met inclusion criteria. The majority were White (50.6%) or African American (40.4%). Median age at medication co-dispensing (45 years), duration of HIV infection (14 years), and duration of ED (1 year) did not differ between the two groups (p>0.05 for all). PDE-5 inhibitors included sildenafil (n = 124), vardenafil (n = 99), and tadalafil (n = 14). ART regimens included RTV-boosted protease inhibitors (PIs) atazanavir (n = 83) or darunavir (n = 34), and COBI-boosted elvitegravir (n = 43). Potential DDIs occurred in 181 (77.0%) participants, of whom 122 (67.4%) had multiple DDI episodes. The median DDI duration was 8 (IQR 1-12) months. In multivariate analyses, non-statistically significant higher odds of DDIs were observed with RTV-boosted PIs or PI-based ART (OR 2.13, 95% CI 0.85-5.37) and in those with a diagnosis of major depressive disorder (OR 1.74, 95% CI 0.83-3.64). Conclusions: PDE-5-mediated DDIs were observed in the majority of males with HIV infection on RTV- or COBI-boosted ART in our cohort. This study highlights the importance of assessing for DDIs among individuals on ART, especially those on boosted regimens. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PloS one, 2021 (prima pubblicazione 2021-05-06). Identificativi: PMID 33956843 · PMCID PMC8101910 · DOI 10.1371/journal.pone.0250607. Descrittori MeSH principali: Drug Interactions. Pagina: https://europepmc.org/article/MED/33956843 — https://doi.org/10.1371/journal.pone.0250607. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-11-04T13:18:36.660Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.